Manipal Hospitals Enterprises Aims To Become Listed Indian Hospital Giant With Fortis Purchase
Bangalore: Manipal Hospitals Enterprises Private Ltd plans to buy Fortis Healthcare Ltd's hospital business to create one of India's largest providers of healthcare and then go public, but the proposed terms sent shares in Fortis tumbling 7 percent.
The combined company will be 38 percent owned by Manipal Chief Executive Ranjan Pai while U.S. buyout firm TPG will hold a 20.7 percent stake. It will be the country's biggest healthcare provider by revenue, Fortis said, posing a formidable rival to Apollo Hospitals Enterprise Ltd.
Under the deal, Fortis shareholders would get 10.83 shares in the combined company, Manipal Hospitals, for every 100 Fortis shares held, Fortis said in a statement. The total value of the transaction was not disclosed.
Fortis has 34 hospitals across India and some other countries including Sri Lanka, while Manipal has 14 hospitals in mostly southern Indian states and Malaysia. Apollo has 64 hospitals, according to its website.
The combined company is expected to seek a listing on the National Stock Exchange and the Bombay Stock Exchange.
The deal offers an out to Fortis backers Malvinder Singh and Shivinder Singh, who resigned from its board last month following legal troubles related to the sale of their stake in drugmaker Ranbaxy to Japan's Daiichi Sankyo Co Ltd.
The Ranbaxy case is unrelated to Fortis.
"We continue to support the management and the board to successfully transition to the new joint entity," the Singh brothers said in a statement late Tuesday.
Manipal also plans to buy a majority stake in diagnostics chain SRL Ltd, purchasing 20 percent from Fortis for roughly 7 billion rupees ($108 million). It is talks to buy 30.9 percent from private-equity investors.
Fortis will hold 36.6 percent of SRL. Without its hospital business, Fortis will become an investment holding company, it said.
(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
